Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | PEGAPAMODUTIDE |
INN | pegapamodutide |
Description | Pegapamodutide is a protein pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Protein |
Drug class | PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer; peptides: oxyntomodulin analogs |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3990012 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | WG4ID2U7FT (ChemIDplus, GSRS) |